PT  - JOURNAL ARTICLE
AU  - Kennalley, Amy L.
AU  - Fanelli, Jessica L.
AU  - Furst, John A.
AU  - Mynarski, Nicholas J.
AU  - Jarvis, Margaret A.
AU  - Nichols, Stephanie D.
AU  - McCall, Kenneth L.
AU  - Piper, Brian J.
TI  - Reversal of increases in methadone distribution for opioid use disorder in the US during the COVID-19 pandemic
AID  - 10.1101/2022.03.09.22272154
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.03.09.22272154
4099  - http://medrxiv.org/content/early/2023/02/15/2022.03.09.22272154.short
4100  - http://medrxiv.org/content/early/2023/02/15/2022.03.09.22272154.full
AB  - Opioid use disorder (OUD) is a major public health concern in the United States (US), resulting in high rates of overdose and other negative outcomes. Methadone, a treatment for OUD, has been shown to be effective in reducing the risk of overdose and improving overall health and quality of life. This study analyzed the distribution of methadone for the treatment of OUD across the US using data from the Drug Enforcement Administration’s Automated Reports and Consolidated Ordering System, Medicaid’s State Drug Utilization Data, and the US Census Bureau. Analysis revealed that methadone distribution for OUD has expanded significantly over the past decade, with an average state increase of +96.96% from 2010 to 2020, and there was a significant increase in overall distribution of methadone to opioid treatment programs (OTP) in the US from 2010 to 2020 (+61.00%) and from 2015 to 2020 (+26.22%). However, the distribution to OTPs did not significantly change from 2019 to 2021 (−5.15%). Furthermore, pronounced variation in methadone distribution among states were observed, with some states having no OTPs or Medicaid coverage. New policies are urgently needed to increase access to methadone treatment and address the opioid overdose crisis in the US.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at the DEA's Automated Reports and Consolidated Ordering System and Medicaid's State Drug Utilization Data.https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.htmlhttps://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medicaid.gov%2Fmedicaid%2Fprescription-drugs%2Fstate-drug-utilization-data%2Findex.html&data=05%7C01%7CAKennalley%40som.geisinger.edu%7Cbf1fa1b23daa469ac51f08daaec32aad%7Cc048947985ac4b82bbad54c03fc21678%7C0%7C0%7C638014450845928960%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=xZLVJRHiS%2BoukxF0vELEvnUhD2aSrTwo3sz5u%2BV7fig%3D&reserved=0